Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo-controlled, double- blind trial

Critical Care Medicine

Volumn 27, Issue 4, 1999, Pages 807-814

  Lauterbach, Ryszard ^a   Pawlik, Dorota ^a   Kowalczyk, Danuta ^a   Ksycínski, Wiesław ^b   Helwich, Ewa ^b   Zembala, Marek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Mother and Child Health Center   (Poland)

Author keywords

Cytokines; Interleukin 1; Interleukin 6; Mortality rate; Pentoxifylline; Premature infants; Sepsis; Septic shock; Tumor necrosis factor

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 6; METHYLXANTHINE DERIVATIVE; PENTILIN; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANURIA; ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MORTALITY; NECROTIZING ENTEROCOLITIS; NEWBORN INTENSIVE CARE; OLIGURIA; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; SEROLOGY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INFUSIONS, INTRAVENOUS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; PENTOXIFYLLINE; PLACEBOS; PROSPECTIVE STUDIES; SEPSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032916980     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199904000-00042     Document Type: Article

References (28)

1. Michie HR, Manogue KR, Spriggs DR, et al: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-1486
2. Baley JE: Neonatal sepsis: the potential for immunotherapy. Clin Perinatol 1988; 4:755-766
3. Hervas JA, Alomar A, Salva F, et al: Neonatal sepsis and meningitis in Mallorca, Spain. Clin Invest Dis 1993; 16:719-723
4. de Bont ES, Martens A, van Raan J, et al: Tumor necrosis factor-α, interleukin-β1, and interleukin-6 plasma levels in neonatal sepsis. Pediatr Res 1993; 33:380-383
5. Sullivan JS, Kilpatrick L, Costarino AT, et al: Correlation of plasma cytokine e levations with mortality rate in children with sepsis. J Pediatr 1992; 120:510-515
6. Masouye P, Gunning K, Pittet JF, et al: Xanthine derivative HWA 138 attenuates hemodynamic and oxygen uptake dysfunction secondary to severe endotoxin shock in sheep. Circ Shock 1992; 36:113-119
7. Lundblad R, Ekstrom P, Giercksky KE: Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intraabdominal sepsis in rats. Shock 1995; 3:210-215
8. Zeni F, Pain P, Vindimian N, et al: Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996; 24:207-214
9. Aderka D: The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996; 7:231-240
10. Rice GC, Brown PA, Nelson RJ, et al: Protection from endotoxic shock in mice by pharmacologic inhibition of phospatidic acid. Proc Natl Acad Sci U S A 1994; 91:3857-3861
11. Lauterbach R, Zembala M: Pentoxifylline reduces plasma tumour necrosis factor-α concentration in premature infants with sepsis. Eur J Pediatr 1996; 155:404-409
12. Hinshaw LB: Sepsis/septic shock: participation of the microcirculation and abbreviated review. Crit Care Med 1996; 24:1072-1078
13. Bell M, Ternberg J, Feigin R: Neonatal necrotizing enterocolitis: therapeutic decision based upon clinical staging. Ann Surg 1978; 187:1-7
14. Tukey J: The philosophy of multiple comparisons. Stat Sci 1991; 6:100-116
15. Bienvenu J, Doche C, Gutowski MC, et al: Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 1995; 25(Suppl 2):80-84
16. Mandi Y, Farkas G, Ocsovszky I: Effects of pentoxifylline and pentaglobin on TNF and IL-6 production in septic patients. Acta Microbiol Hung 1995; 42:301-308
17. Beutler B, Cerami A: Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316:379-385
18. Mock CN, Jurkovich GJ, Dries D, et al: The clinical significance of endotoxin released by antibiotics: what is the evidence? J Endotox Res 1996; 3:253-260
19. Endo S, Inada K, Inoue Y, et al: Two types of septic shock classified by the plasma levels of cytokines and endotoxin. Circ Shock 1992; 38:264-274
20. Krysztopik RJ, Bentley FR, Wilson MA, et al: Vasomotor response to pentoxifylline mediates improved renal blood flow to bacteremia. J Surg Res 1996; 63:17-22
21. Wang P, Wood TJ, Ba ZF, et al: Pentoxifylline maintains vascular endothelial cell function during hyperdynamic and hypodynamic sepsis. Surgery 1996; 120:367-373
22. Boldt J, Muller M, Heesen M, et al: Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Crit Care Med 1996; 24:385-391
23. Boldt J, Muller M, Heesen M, et al: The effects of pentoxifylline on circulating ad hesion molecules in critically ill patients with acute renal failure treated by conti nuous veno-venous hemofiltration. Intensive Care Med 1996; 22:305-311
24. Mandi Y, Farkas G, Ocsovszky I, et al: Inhibition of tumor necrosis factor produc tion and ICAM-1 expression by pentoxifylline: beneficial effects in sepsis syndrome. Res Exp Med (Berl) 1995; 195:297-307
25. Steeb GD, Wilson MA, Garrison RN: Pentoxifylline preserves small-intestine microvascular blood flow during bacteriemia. Surgery 1992; 112:756-764
26. Davidson LW, Mollitt DL: The effect of endotoxin on red blood cell deformability and whole blood viscosity. Curr Surg 1990; 47:341-345
27. Boldt J, Muller M, Heyn S, et al: Influence of long-term continuous intravenous administration of pentoxifylline on endothelial-related coagulation in critically ill patients. Crit Care Med 1996; 24:940-946
28. Sato K, Stelzner TJ, O'Brien RF, et al: Pentoxifylline lessens the endotoxin-induced increase in albumin clearance across pulmonary artery endothelial monolayers with and without neutrophils. Am J Respir Cell Mol Biol 1991; 4:219-227